Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study

Stephanie Scarmo, Yelena Afanasyeva, Per Lenner, Karen L. Koenig, Ronald L. Horst, Tess V. Clendenen, Alan A. Arslan, Yu Chen, Göran Hallmans, Eva Lundin, Sabina Rinaldi, Paolo Toniolo, Roy E. Shore, Anne Zeleniuch-Jacquotte

Research output: Contribution to journalArticle

Abstract

Introduction: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent.Methods: We conducted a case-control study nested within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at enrollment, and women were followed up for breast cancer ascertainment. In total, 1,585 incident breast cancer cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.Results: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk (multivariate-adjusted model OR = 0.94, 95% CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend = 0.30). The temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for season-adjusted 25(OH)D > 0.70). An inverse association between 25(OH)D levels and breast cancer risk was observed among women who were ≤ 45 years of age (ORQ5-Q1 = 0.48, 95% CI = 0.30-0.79, ptrend = 0.01) or premenopausal at enrollment (ORQ5-Q1 = 0.67, 95% CI = 0.48-0.92, ptrend = 0.03).Conclusions: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D supplementation should be based on considerations other than breast cancer prevention.

Original languageEnglish (US)
Article numberR15
JournalBreast Cancer Research
Volume15
Issue number1
DOIs
StatePublished - Feb 26 2013

Fingerprint

Case-Control Studies
Breast Neoplasms
Confidence Intervals
Odds Ratio
Women's Health
25-hydroxyvitamin D
Sweden
Vitamin D
Epidemiologic Studies
Breast
Logistic Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Scarmo, S., Afanasyeva, Y., Lenner, P., Koenig, K. L., Horst, R. L., Clendenen, T. V., ... Zeleniuch-Jacquotte, A. (2013). Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study. Breast Cancer Research, 15(1), [R15]. https://doi.org/10.1186/bcr3390

Circulating levels of 25-hydroxyvitamin D and risk of breast cancer : A nested case-control study. / Scarmo, Stephanie; Afanasyeva, Yelena; Lenner, Per; Koenig, Karen L.; Horst, Ronald L.; Clendenen, Tess V.; Arslan, Alan A.; Chen, Yu; Hallmans, Göran; Lundin, Eva; Rinaldi, Sabina; Toniolo, Paolo; Shore, Roy E.; Zeleniuch-Jacquotte, Anne.

In: Breast Cancer Research, Vol. 15, No. 1, R15, 26.02.2013.

Research output: Contribution to journalArticle

Scarmo, S, Afanasyeva, Y, Lenner, P, Koenig, KL, Horst, RL, Clendenen, TV, Arslan, AA, Chen, Y, Hallmans, G, Lundin, E, Rinaldi, S, Toniolo, P, Shore, RE & Zeleniuch-Jacquotte, A 2013, 'Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study', Breast Cancer Research, vol. 15, no. 1, R15. https://doi.org/10.1186/bcr3390
Scarmo S, Afanasyeva Y, Lenner P, Koenig KL, Horst RL, Clendenen TV et al. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study. Breast Cancer Research. 2013 Feb 26;15(1). R15. https://doi.org/10.1186/bcr3390
Scarmo, Stephanie ; Afanasyeva, Yelena ; Lenner, Per ; Koenig, Karen L. ; Horst, Ronald L. ; Clendenen, Tess V. ; Arslan, Alan A. ; Chen, Yu ; Hallmans, Göran ; Lundin, Eva ; Rinaldi, Sabina ; Toniolo, Paolo ; Shore, Roy E. ; Zeleniuch-Jacquotte, Anne. / Circulating levels of 25-hydroxyvitamin D and risk of breast cancer : A nested case-control study. In: Breast Cancer Research. 2013 ; Vol. 15, No. 1.
@article{9b81be92f3ce4e289f7edc8958838d5d,
title = "Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested case-control study",
abstract = "Introduction: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent.Methods: We conducted a case-control study nested within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at enrollment, and women were followed up for breast cancer ascertainment. In total, 1,585 incident breast cancer cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds ratios (ORs) and 95{\%} confidence intervals (CIs) were calculated using conditional logistic regression.Results: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk (multivariate-adjusted model OR = 0.94, 95{\%} CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend = 0.30). The temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for season-adjusted 25(OH)D > 0.70). An inverse association between 25(OH)D levels and breast cancer risk was observed among women who were ≤ 45 years of age (ORQ5-Q1 = 0.48, 95{\%} CI = 0.30-0.79, ptrend = 0.01) or premenopausal at enrollment (ORQ5-Q1 = 0.67, 95{\%} CI = 0.48-0.92, ptrend = 0.03).Conclusions: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D supplementation should be based on considerations other than breast cancer prevention.",
author = "Stephanie Scarmo and Yelena Afanasyeva and Per Lenner and Koenig, {Karen L.} and Horst, {Ronald L.} and Clendenen, {Tess V.} and Arslan, {Alan A.} and Yu Chen and G{\"o}ran Hallmans and Eva Lundin and Sabina Rinaldi and Paolo Toniolo and Shore, {Roy E.} and Anne Zeleniuch-Jacquotte",
year = "2013",
month = "2",
day = "26",
doi = "10.1186/bcr3390",
language = "English (US)",
volume = "15",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Circulating levels of 25-hydroxyvitamin D and risk of breast cancer

T2 - A nested case-control study

AU - Scarmo, Stephanie

AU - Afanasyeva, Yelena

AU - Lenner, Per

AU - Koenig, Karen L.

AU - Horst, Ronald L.

AU - Clendenen, Tess V.

AU - Arslan, Alan A.

AU - Chen, Yu

AU - Hallmans, Göran

AU - Lundin, Eva

AU - Rinaldi, Sabina

AU - Toniolo, Paolo

AU - Shore, Roy E.

AU - Zeleniuch-Jacquotte, Anne

PY - 2013/2/26

Y1 - 2013/2/26

N2 - Introduction: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent.Methods: We conducted a case-control study nested within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at enrollment, and women were followed up for breast cancer ascertainment. In total, 1,585 incident breast cancer cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.Results: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk (multivariate-adjusted model OR = 0.94, 95% CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend = 0.30). The temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for season-adjusted 25(OH)D > 0.70). An inverse association between 25(OH)D levels and breast cancer risk was observed among women who were ≤ 45 years of age (ORQ5-Q1 = 0.48, 95% CI = 0.30-0.79, ptrend = 0.01) or premenopausal at enrollment (ORQ5-Q1 = 0.67, 95% CI = 0.48-0.92, ptrend = 0.03).Conclusions: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D supplementation should be based on considerations other than breast cancer prevention.

AB - Introduction: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent.Methods: We conducted a case-control study nested within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at enrollment, and women were followed up for breast cancer ascertainment. In total, 1,585 incident breast cancer cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.Results: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk (multivariate-adjusted model OR = 0.94, 95% CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend = 0.30). The temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for season-adjusted 25(OH)D > 0.70). An inverse association between 25(OH)D levels and breast cancer risk was observed among women who were ≤ 45 years of age (ORQ5-Q1 = 0.48, 95% CI = 0.30-0.79, ptrend = 0.01) or premenopausal at enrollment (ORQ5-Q1 = 0.67, 95% CI = 0.48-0.92, ptrend = 0.03).Conclusions: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D supplementation should be based on considerations other than breast cancer prevention.

UR - http://www.scopus.com/inward/record.url?scp=84874199657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874199657&partnerID=8YFLogxK

U2 - 10.1186/bcr3390

DO - 10.1186/bcr3390

M3 - Article

C2 - 23442740

AN - SCOPUS:84874199657

VL - 15

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 1

M1 - R15

ER -